Merck Sharp + Dohme Corp.

Pharmacopeia Inc.

Xiaoiang Liu

William J Greenlee

Andrew William Stamford

Jared N Cumming

Zhaoning Zhu

Brian Alexander McKittrick

Tao Guo

Elizabeth M Smith

Ying Huang

Corey Strickland

Ulrich Iserloh

Guoqing Li

Suresh D Babu

Robert D Mazzola, Jr

Yusheng Wu

Lingyan Wang

Kurt William Saionz

John P Caldwell

Zhong-Yue Sun

Yuanzan C Ye

Jianping Pan

Yuefei Shao

Rachael Catherine Hunter

Gang Qian

Michelle Lee Morris

Huizhong Gu

Dawit Tadesse

Gaifa Lai

Jeffrey A Misiaszek

Jingqi Duo

Johannes H Voight

Chuanxing Qu

Thuy X E Le

Thuy Xe Le

Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein each variable in Formula 1 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic magonist or mantagonist.

Heterocyclic aspartyl protease inhibitors

Growing community of inventors

River Vale, NJ, United States of America

Xiaoiang Liu